Quarter Ended: March 2026
Laurus Labs Limited – Q4 FY26 Results
NSE
lauruslabs
BSE
540222
Laurus Labs delivered a strong YoY turnaround in profitability with improved operating efficiency, while maintaining stable QoQ performance. Cash flow generation remains robust despite higher capex
key financial highlights
- Revenue from Operations:
- Revenue (Q4 FY26): ₹1,811.6 Cr
- QoQ Change: +5.3%
- YoY Change: +1.9%
- Previous Quarter (Q3 FY26): ₹1,778.3 Cr
- Previous Year (Q4 FY25): ₹1,720.3 Cr
- Revenue (Q4 FY26): ₹1,811.6 Cr
- Profit After Tax (PAT):
- PAT (Q4 FY26): ₹282.1 Cr
- QoQ Change: +20.6%
- YoY Change: +12.0%
- Previous Quarter (Q3 FY26): ₹251.9 Cr
- Previous Year (Q4 FY25): ₹232.8 Cr
- PAT (Q4 FY26): ₹282.1 Cr
- QoQ Performance
- Revenue Trend: Stable growth
- Profit Trend: Improving
Margin Analysis
Drivers:
- Operating leverage from higher scale
- Controlled finance costs
- Improvement in product mix
- Lower volatility in input costs
Insight:
- Margins are expanding, indicating recovery phase and improving efficiency
Earning quality check
Drivers:
- Strong operating cash flow: ₹1,623.5 Cr
- Profit backed by core operations (not one-offs)
- Stable depreciation and finance cost structure
- Controlled working capital adjustments
Interpretations:
- High-quality earnings supported by strong cash conversion and operational strength
balance sheet Analysis
- Total Assets: ₹10,511.19 Cr
- Total Liabilities: ₹5,079.83 Cr (derived)
Insight:
- Strong equity base (~₹5,431 Cr)
- Controlled leverage with moderate borrowings
- Increase in assets driven by capex and working capital expansion
key risks
- High capex leading to pressure on free cash flow
- Dependence on global pharma demand cycles
- Currency fluctuations impacting export realizations
- Working capital intensity (inventory + receivables increase)
management strategy signals
Focus Area:
- Capacity expansion and capex deployment
- Strengthening CDMO and API segments
- Improving operating efficiencies
- Scaling high-margin segments
Financial metrics table
| Particular | Q4 FY26 | Q.O.Q | Y.O.Y |
|---|---|---|---|
| Revenue | ₹1,811.6 Cr | +1.9% | +5.3% |
| Total Expense | ₹1,462.0 Cr | Stable | +~6.0% |
| Net Profit | ₹282.1 Cr | -50.9% | +20.6% |
Laurus Labs is clearly in a recovery and growth phase, with improving margins, strong cash flows, and consistent profit growth. While capex remains high, the company is building long-term capacity, making it structurally stronger. Short-term risks exist from working capital and global demand cycles, but overall trajectory remains positive.
Official Exchange Filing: Laurus Labs Limited
Quarterly Performance Context
COST OF OPERATIONS AS % OF REVENUE
80%
NET PROFIT AS % OF REVENUE
16%
FISCAL YEAR
2025-2026
AUDIT STATUS
REVIEWED